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Alzheimer’s disease (AD) is a neurodegenerative disorder characterized clinically by the
progressive decline of memory and cognition. Histopathologically, two main hallmarks
have been identified in AD: amyloid-β peptide extracellular neuritic plaques and
neurofibrillary tangles formed by posttranslational modified tau protein. A definitive
diagnosis can only be achieved after the post mortem verification of the histological
mentioned alterations. Therefore, the development of biomarkers that allow an early
diagnosis and/or predict disease progression is imperative. The prospect of a blood-based
biomarker is possible with the finding of circulating microRNAs (miRNAs), a class of
small non-coding RNAs of 22–25 nucleotides length that regulate mRNA translation
rate. miRNAs travel through blood and recent studies performed in potential AD cases
suggest the possibility of finding pathology-associated differences in circulating miRNA
levels that may serve to assist in early diagnosis of the disease. However, these studies
analyzed samples at a single time-point, limiting the use of miRNAs as biomarkers in
AD progression. In this study we evaluated miRNA levels in plasma samples at different
time-points of the evolution of an AD-like pathology in a transgenic mouse model of
the disease (3xTg-AD). We performed multiplex qRT-PCR and compared the plasmatic
levels of 84 miRNAs previously associated to central nervous system development and
disease. No significant differences were detected between WT and transgenic young
mice. However, age-related significant changes in miRNA abundance were observed for
both WT and transgenic mice, and some of these were specific for the 3xTg-AD. In
agreement, variations in the levels of particular miRNAs were identified between WT
and transgenic old mice thus suggesting that the age-dependent evolution of the AD-like
pathology, rather than the presence and expression of the transgenes, modifies the
circulating miRNA levels in the 3xTg-AD mice.
Keywords: early diagnosis, neurodegenerative diseases, blood-based biomarker, Alzheimer models, plasma,
pathological aging, prognosis, 3x-Tg
INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of demen-
tia clinically characterized by the progressive decline of memory.
At the histopathological level two main hallmarks define it: the
abnormal extracellular accumulation of amyloid-β peptide (Aβ)
into neuritic plaques and the formation of intraneuronal neu-
rofibrillary tangles (NFTs) composed by posttranslational mod-
ified tau protein. These pathological markers are mainly located
in hippocampus and cortical regions (Selkoe, 2001; Ballard et al.,
2011) and are accompanied by synaptic loss early in the disease,
which constitutes the major morphological correlate of mem-
ory decline (Terry et al., 1991; Dekosky et al., 1996). AD is the
major neurodegenerative disorder in the elderly; the prevalence
of the disease increases with age, thus aging constitutes the main
risk factor (World Alzheimer Report, ADI, 2009). Two recognized
forms of the disease include the sporadic AD (SAD) and the famil-
ial AD (FAD). SAD accounts for more than 99% of total cases and
is characterized by a late-onset of symptomatology, whereas FAD
is an early-onset form of the disease associated with mutations
in three genes encoding for the amyloid precursor protein (APP),
presenilin 1 (PS1), and presenilin 2 (PS2) transmitted in an auto-
somal dominant pattern (Goate et al., 1991; Levy-Lahad et al.,
1995; Rogaev et al., 1995; Sherrington et al., 1995).
Currently, amyloid-imaging positron emission tomography
(PET) through the Pittsburgh Compound-B (PIB) tracer is the
best tool for identifying amyloid deposits in patients (Klunk et al.,
2004; Alkalay et al., 2013). However, a definitive diagnosis of
AD can only be achieved after post mortem histopathological
verification. Therefore, the development of sensitive and spe-
cific non-invasive methods to detect molecular markers or to
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best predict the disease progression is crucial. Among different
prospects of a blood-based biomarker, the finding that circulat-
ing microRNAs (miRNAs) derived from different types of cells
can be detected, make possible their use as non-invasive mark-
ers of brain dysfunction. miRNAs are small non-coding RNAs
of 22–25 nucleotides length that posttrancriptionally regulate the
level of many proteins via mRNA silencing or degradation (Bartel,
2009; Fabian and Sonenberg, 2012; Ameres and Zamore, 2013).
They travel through blood within specialized vesicles known as
exosomes, associated with protein complexes or into high den-
sity lipoproteins as well (Valadi et al., 2007; Arroyo et al., 2011;
Vickers et al., 2011). Because endogenous miRNAs are protected
in circulation, they are highly stable and their levels can be ana-
lyzed by conventional techniques of molecular biology through
which changes in circulating miRNA levels have been associated
with diverse pathologies (Chen et al., 2008; Lawrie et al., 2008;
Mitchell et al., 2008).
Analysis of miRNA profiles in post mortem brain and cere-
brospinal fluid (CSF) samples of AD patients have revealed
changes in miRNA levels associated to the disease (Lukiw, 2007;
Cogswell et al., 2008; Hébert et al., 2008; Wang et al., 2008b,
2011; Nunez-Iglesias et al., 2010; Alexandrov et al., 2012; Müller
et al., 2014). Recent studies performed in plasma samples of
potential AD cases suggest the possibility of finding differences
between circulating miRNA levels of AD cases and control sub-
jects (Geekiyanage et al., 2011; Kumar et al., 2013; Leidinger et al.,
2013; Tan et al., 2013; Burgos et al., 2014; Kiko et al., 2014). In this
regard, studies have aimed at analyzing miRNA levels at a single
time-point, which may limit their use as biomarkers or as disease
predictors. The possibility to evaluate circulating miRNA levels at
different time-points in the progression of the disease could pro-
vide information regarding key physiopathological features of AD
and could contribute in establishing early blood-based molecular
biomarkers for the disease. AnalyzingmiRNA levels in blood sam-
ples from patients at an early time-point is hampered by the fact
that symptoms do not develop until the disease is at an advanced
stage. Thus, in this study we used the triple transgenic mouse
model (3xTg-AD) which reproduces the age-dependent progress
of amyloid pathology and develops the tauopathy similar to that
found in AD (Oddo et al., 2003). In order to evaluate specific
miRNA levels in plasma samples at different time-points of the
evolution of the AD-like pathology, we performedmultiplex qRT-
PCR and compared the levels from 3xTg-AD and WT mice of 84
miRNAs previously associated to central nervous system (CNS)
development (Giraldez et al., 2005; Yoo et al., 2009; Zhao et al.,
2009; Edbauer et al., 2010) and diseases such as schizophrenia
(Beveridge et al., 2010), Huntington disease (Johnson et al., 2008),
Parkinson disease (Kim et al., 2007; Wang et al., 2008a), and AD.
No significant differences in circulating miRNA levels were
detected between 3xTg-AD and WT young mice. However, age-
related significant changes in the abundance of certain plas-
matic miRNAs were observed in both WT and transgenic mice.
Interestingly, some of the miRNAs that changed were specific
for the 3xTg-AD. In agreement, variations in the abundance of
particular miRNAs were identified between WT and transgenic
old mice thus suggesting that the age-dependent evolution of
AD-like pathology, rather than the presence and expression of
human transgenes, modifies the circulating miRNA profile in the
3xTg-AD mice.
MATERIALS AND METHODS
ANIMALS
Homozygous 3xTg-AD developed by Oddo et al. (2003) (n = 14)
and wild-type (WT) (n = 13) male mice (strain 129/C57BL6)
were used in the study. For developing the transgenic mice,
human APP cDNA harboring the Swedish double mutation
(KM670/671NL) and human tau cDNA harboring the P301L
mutation were cloned into Thy1.2 expression cassette and co-
microinjected into single-cells embryos harvested from homozy-
gous PS1M146V knockin (KI) mice generated as a hybrid
129/C57BL6 background. For this study, all used 3xTg-AD mice
were genotyped by identifying the three harbored human trans-
genes (Supplementary Figure 1). Brains from four 3xTg-ADmale
mice 2–3 (n = 2) and 14–15 (n = 2) months old were used
for immunohistochemical analysis. Determination of circulating
miRNA profiles included blood samples from six-seven animals
per group and a total of four experimental groups were integrated:
2–3 months old-3xTg-AD mice (n = 6), 2–3 months old-WT
mice (n = 6), 14–15 months old-3xTg-AD (n = 6), and 14–15
months old-WT mice (n = 7). The experiments were performed
in accordance with local government rules and the Society for
Neuroscience Guide for the Care and Use of Laboratory Animals
with approval of the Animal Care Committee of the Instituto de
Investigaciones Biomedicas, UNAM. Efforts were made to min-
imize animal suffering and to reduce the number of subjects
used.
GENOTYPING
Genomic DNA was isolated from the 3xTg-AD mice tails
(2–3mm) by the Hot-Shot method. Tail samples were homoge-
nized with alkaline lysis reagent (25mM NaOH, 0.2mM EDTA,
pH 12) through mechanical action and incubated during 1 h at
95◦C. Tris-HCl buffer (40mM, pH 5) was added to each sam-
ple for neutralization (pH 7.5). Samples were centrifuged during
2min at 12 500 rpm, 4◦C, and the supernatant was used for
PCR amplification. Human APPSwe and tauP301L transgenes were
identified through their amplification products of 500 bp and
320 bp, respectively into a 2% agarose gel stained with ethid-
ium bromide. The primers used for APP-tau PCR were 5tauRev
(5′-TCCAAAGTTCACCTGATAGT-3′), APPinternal (5′-GCTTG
CACCAGTTCTGGATGG-3′) and Thy12.4 (5′-GAGGTATTC
AGTCATGTGCT-3′). PS1M146V KI was detected by a PCR using
the PS1-K13 (5′-CACACGCACACTCTGACATGCACAGGC-3′)
and PS1-K15 (5′-AGGCAGGAAGATCACGTGTTCCAAGTAC-
3′) primers, followed by an enzymatic digestion (1 h, 60◦C) with
endonuclease BstEII (New England Biolabs). Products were sepa-
rated into a 2% agarose gel, and identified as a 530 bp band from
WT PS1, or 350 bp and 180 bp bands frommutation carriers PS1.
IMMUNOHISTOCHEMISTRY
3xTg-AD mice (n = 4) were anesthetized with sodium pento-
barbital and transcardially perfused with 0.9% chilled saline
followed by 4% chilled formaldehyde in 0.1M phosphate buffer
(pH 7.4). Brains were extracted and post-fixed during 24 h at
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4◦C. Subsequently, brains were transferred to 15 and 30% sucrose
solutions in 0.1M phosphate buffer for 24 h in each concentra-
tion. 30μm-thick coronal sections were obtained in a cryostat
(MicromHM550, Thermo Scientific). Free-floating sections were
collected in 24-well plates (Corning) and were washed for 10, 15,
and 30min with 0.15M PBS and 0.4% PBS-triton solutions. They
were then incubated in blocking solution (0.4% PBS-triton, 3%
NGS) during 2 h at room temperature, followed by an overnight
incubation at 4◦C with 1:500 dilution of the primary antibody,
either the MAB1560 6E10 clone (Chemicon) which recognizes
aminoacids 1–17 from human Aβ peptide, or the MN1020 α-p-
PHF-tau AT8 clone (Pierce, Thermo Scientific) which recognizes
phosphorylated serine 202 and threonine 205 from human tau
protein. Sections were washed as previously detailed and were
then incubated in a 1:250 dilution of the secondary α-mouse anti-
body, either Alexa-488 or Alexa-555 for 2 h at room temperature.
Finally, sections were washed for 10, 15, and 30min in 0.15M
PBS, incubated for 3min in 30 nM DAPI, and washed again.
Immunofluorescence was detected using a Zeiss epifluorescence
microscope under 10X and 60X.
DETERMINATION OF CIRCULATING miRNA LEVELS
Plasma collection
Blood samples were collected from 3xTg-AD and WT mice at 2–
3 and 14–15 months of age. ∼500μL of blood were obtained
from the facial vein of each mouse and collected into a new
and sterile 1.5mL centrifuge tube containing 10μL of 300mM
EDTA used as anticoagulant. Plasma was separated through two
centrifugations, one at low (3000 rpm) and another at high
(13,000 rpm) speed, both at 4◦C for 10min. For determining cir-
culating miRNA profiles, equal volumes of plasma samples from
two mice within the same experimental group were pooled after
plasma separation and a total of three different pools per experi-
mental group were included in the analysis. Pooled samples were
stored in ice and immediately treated following the RNA isolation
protocol.
RNA isolation
RNA was isolated from each pool using the miRNeasy
Serum/Plasma Kit (Qiagen) following the manufacturer instruc-
tions. Briefly, 200μL of pooled plasma were homogenized with
1000μL of Qiazol Lysis Reagent. After homogenization, 3.5μL of
a 1.6 × 108 copies/μL solution of the C. elegans miR-39 miRNA
mimic used as a spike-in control were added to each sample.
Then, a phenol-chloroform extraction was performed by incu-
bating the sample in 200μL of chloroform for 5min at room
temperature and centrifuging for 15min at 12,000 rpm at 4◦C.
The aqueous phase was mixed with 1.5 volumes of 100% ethanol
and passed through the RNeasy MinElute spin column. The RNA
retained in the membrane was washed with buffer solutions, 80%
ethanol and eluted in 14μL of RNase free water. RNA sam-
ples were stored in ice and immediately treated for qRT-PCR
protocols.
qRT-PCR
miRNA levels from plasma of 3xTg-AD and WT mice 2–3 and
14–15 months old were determined using the miScript miRNA
PCR Array System (Qiagen). The System consists in three dif-
ferent kits: the miScript II RT Kit which performs the cDNA
synthesis, the miScript SYBR Green PCR Kit which prepares
the mix for qPCR reactions, and the Pathway-Focused miScript
miRNA PCR Array “Neurological Development and Disease”
which detects 84 different miRNAs previously associated with
CNS development and disease. For the cDNA synthesis, 1.5μL
of RNA isolated from plasma were used as the starting material
of a 20μL-reaction that consists of a universal synthesis driven by
the addition of a poly-A tail and an oligo-dT that selectively retro-
transcribes the small RNAmolecules (<100 nucleotides) avoiding
the retrotranscription of miRNA precursors. The reaction was
incubated for 1 h at 37◦C followed by a 5min-incubation at 95◦C
to inactivate the RTase enzyme. cDNA from each sample was
diluted by adding 200μL of RNase free water and stored at−20◦C
overnight. After thawing the cDNA on ice, 100μL of sample were
added to the qPCR reaction mix using SYBR Green as a detec-
tor. 20μL of qPCR reaction mix were added to each well of the
array. The multiplex qPCR was performed using the Rotor Gene
6000 under the following conditions: pre-incubation for 15min
at 95◦C, 40 denaturation-alignment-elongation (15 s at 94◦C, 30 s
at 55◦C, and 30 s at 70◦C) cycles and a dissociation melt protocol.
DATA ANALYSIS
Data were analyzed using the Ct (2−Ct) method of rela-
tive quantification with the support of the data analysis soft-
ware for miScript miRNA PCR Arrays available for users
at http://pcrdataanalysis.sabiosciences.com/mirna. The settings
were manually fixed at 10 cycles of baseline and 0.02 of threshold
line across all PCR runs. The software calculated the Ct value
between the threshold cycle value (Ct) of each miRNA and the Ct
of the C. elegans miR-39 miRNA mimic spike-in control used for
normalization. The software also calculated the (2−Ct) value of
each miRNA between arrays from different experimental groups.
Each experimental group consisted of three samples (n = 3) and
each sample contained the pooled plasma from two animals. The
mean of the relative abundance ± SD of each miRNA contained
in the samples (n = 3) was calculated. The statistical significance
between miRNAs was determined by a t-test. A dissociation curve
analysis was performed to guarantee the presence of only one PCR
product.
RESULTS
In order to detect possible variations in the circulating miRNA
profiles related to the AD-like pathology present in the 3xTg-AD
transgenic mice, we evaluated the levels of 84 miRNAs previously
associated to CNS development and disease in plasma samples
of 3xTg-AD and WT mice 2–3 and 14–15 months old. As previ-
ously shown (Oddo et al., 2003), these two time-points represent
different stages of evolution of the pathological features in the
3xTg-AD mice: at 2–3 months old, histopathological markers
are not evidently expressed in the hippocampus whereas at 14–
15 months old they become clear in cortical and hippocampal
regions. The 2–3month old-3xTg-ADmice express human trans-
genes; nevertheless at this time-point we did not find extracellular
amyloid aggregates in the hippocampus and scarce phospho-
tau (p-tau) immunoreactivity for AT8 was observed (Figure 1A).
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FIGURE 1 | Development of AD-like histopathological features in the
3xTg-AD. Brain coronal sections from the hippocampal CA1 field of
3x-Tg-AD mice. (A) Two- to three-month-old mice sections show Aβ (green)
and p-tau (red) human transgene expression. Bottom panels correspond to
magnifications of delineated regions in top images; arrows point at Aβ (left)
and p-tau (right) immunostaining with no evidence of AD-like
histopathological features. (B) Fourteen- to fifteen-month-old mice sections
show extracellular aggregates of Aβ (green) and neuronal processes
containing p-tau (red). Bottom panels correspond to magnifications of
delineated regions in top images; arrowheads point at features indicative of
the presence of AD histopathological hallmarks. Scale bars in (A) and (B):
100μm (top images) and 20μm (bottom images).
As previously reported (Oddo et al., 2003) we found that the
14–15 month old-3xTg-AD mice display extracellular amyloid
aggregates. Also, neuronal somata and processes were strongly
immunopositive for p-tau in AD relevant residues (Figure 1B).
ABUNDANCE OF CNS DEVELOPMENT- AND DISEASE-LINKED miRNAs
IN MOUSE PLASMA
Most of the 84 evaluated miRNAs were detected in mice plasma
from all analyzed groups (Supplementary Tables 1–4). Highly
abundant detected miRNAs belong to the let-7 family, miR-15
family, miR-30 family, miR-24-27 cluster, miR-29 cluster, miR-
17-92 cluster and its paralogs miR-106a-363 and miR-106b-25
that are characterized by their presence in multiple cell lineages
as well as by their role in fundamental cellular processes. We
found a group of less or not detected miRNAs such as miR-135b,
miR-302a/b, miR-488, and miR-9. The plasmatic abundance of
detected miRNAs was compared between groups. No signifi-
cant differences were observed in the circulating miRNA profile
from 2–3 months-old 3xTg-AD mice when compared to the
age-matched WT group (Supplementary Table 1).
When comparing the circulating miRNA profile between the
young and the old mice for both WT and 3xTg-AD, we found
that aging associated with changes in the plasmatic levels of
a group of miRNAs. We detected significant differences in the
levels of 33 miRNAs when comparing old vs. young WT mice
and in 40 miRNAs when comparing old vs. young 3xTg-AD
mice; 19 of these miRNAs were common to both comparisons
(Figure 2, Supplementary Tables 2,3). These overlappingmiRNAs
include family members of let-7, miR-30, miR-17-92 cluster and
its paralogs. When comparing young vs. old 3xTg-AD mice, we
identified a particular group of miRNAs integrated by miR-132,
miR-138, miR-146a, miR-146b, miR-22, miR-24, miR-29a, miR-
29c, and miR-34a which show significant differences in plasma
levels only in the transgenic group, raising the possibility of
age-related changes that specifically occur in the 3xTg-AD mice
(Figure 3, Supplementary Table 3).
PATHOLOGY-RELATED CHANGES IN THE RELATIVE ABUNDANCE OF
PLASMATIC miRNAs
When comparing the plasma of 14–15 months old 3xTg-ADmice
vs. age-matched WT mice, we detected a significant lower abun-
dance of miR-132, miR-138, miR-139, miR-146a, miR-146b, miR-
22, miR-24, miR-29a, and miR-29c as well as a higher abundance
of miR-346 (Figure 4, Supplementary Table 4). This finding sug-
gests that the relative abundance of these miRNAs was altered
specifically in the 3xTg-AD mice only at age 14–15 months since
they were not altered at 2–3 months of age. These results correlate
with the appearance of the histopathological features (Figure 1).
DISCUSSION
AD is a neurodegenerative disorder highly related to aging
that exhibits progressive manifestations at both clinical and
histopathological levels. The evolution of AD neuropathological
features in the 3xTg-AD is also age-dependent (Oddo et al., 2003).
In this work, we evaluated the levels of circulatingmiRNAs in four
groups of animals: young WT; young 3xTg-AD; old WT and; old
3xTg-AD. For this purpose, we pooled plasma from two differ-
ent animals from the same group and conformed three samples
per group. Obtaining sufficient plasma for miRNA isolation can
be problematic with young animals and getting sufficient animals
with the triple transgene is difficult especially with old animals,
since their health declines rapidly andmortality increases. Pooling
the samples on the one hand, may pose a limitation given that
each sample contains plasma from two different animals. But on
the other hand, this design allowed us to avoid the bias from
changes in circulatingmiRNAs associated to each individual. Even
when the 3xTg-AD already bears the pathological transgenes, we
did not find changes in the circulating miRNA profile between
WT and 3xTg-AD young mice. This suggests that the presence
of the transgenes is not sufficient to modify the circulating levels
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FIGURE 2 | Significant age-related changes in plasmatic miRNAs in WT
and 3x-Tg-AD analyzed by qRT-PCR. (A) The Venn diagram depicts the
number of miRNAs showing statistically different plasma levels between
young and old mice in WT (33 miRNAs, in light gray) and in 3xTg-AD mice (40
miRNAs, in black) as shown by a t-test; p < 0.05. From these miRNAs, 19 are
common to both comparisons (dark gray). (B) Relative abundance among
groups of each of the 19 matching miRNAs. Relative abundance was
calculated considering the difference of the Ct of each miRNA and the Ct of
the miR-39 of C. elegans mimic (Ct) using the formula 2−Ct. miR-39 from
C. elegans was used as spike-in control in all qRT-PCR experiments. Only
miRNAs that showed statistical differences when comparing young and old
WT or Tg subjects are shown in the graph; t-test; p < 0.05.
FIGURE 3 | Significant age-dependent changes in plasmatic miRNAs in
the 3xTg-AD analyzed by qRT-PCR. The graph depicts the relative
abundance (mean ± SD) of each one of the miRNAs that show statistically
significant differences (t-test; p < 0.05) in plasma levels between the 2–3
and the 14–15 months-old 3xTg-AD mice. Relative abundances were
calculated with the difference of the Ct of each miRNA and the Ct of the
miR-39 of C. elegans mimics (Ct) using the formula 2−Ct. Determination
of circulating miRNA profiles included plasma samples from six-seven
animals per group and a total of four experimental groups were integrated:
2–3 months old-3xTg-AD mice (n = 3), 2–3 months old-WT mice (n = 3),
14–15 months old-3xTg-AD (n = 3), and 14–15 months old-WT mice (n = 3)
(n = samples).
FIGURE 4 | Significant differences in the abundance of plasmatic
miRNAs between aging groups analyzed by qRT-PCR. The graph depicts
the relative abundance (mean ± SD) of each one of the miRNAs that show
statistically significant differences (t-test; p < 0.05) in plasma levels
between 14–15 months-old WT and 3xTg-AD mice. Relative abundances
were calculated with the difference of the Ct of each miRNA and the Ct of
the miR-39 of C. elegans mimics (Ct) using the formula 2−Ct.
Determination of circulating miRNA profiles included plasma samples from
six-seven animals per group and a total of four experimental groups were
integrated: 2–3 months old-3xTg-AD mice (n = 3), 2–3 months old-WT mice
(n = 3), 14–15 months old-3xTg-AD (n = 3), and 14–15 months old-WT mice
(n = 3) (n = samples).
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of miRNAs at early stages of the pathology. Nevertheless, we
found age-related changes in the plasmatic abundance of certain
miRNAs in both WT and 3xTg-AD mice. Remarkably we found
changes in specific circulating miRNAs in the aging AD model.
In agreement with other studies (Grillari et al., 2010; Kato et al.,
2011; Martinez et al., 2011) we found a decrease in abundance of
members of the family of let-7, miR-30, miR-17-92 cluster and its
paralogs miR-106a-363 and miR-106b-25 in WT and 3x-Tg-AD
aged mice. Let-7 family is highly involved in developmental pro-
cesses inmultiple species; it is required for cell differentiation thus
its levels increase in late developmental stages and remain high in
the adult (Thomson et al., 2004). Accordingly, let-7 family mem-
bers target important cell cycle molecules (Schultz et al., 2008).
miR-17-92 cluster and its paralogs are other important cell cycle
modulators; interestingly, they are up-regulated in cancer and
suppression of these clusters’ members induce cell growth arrest
in cancer models, whereas they are down-regulated in aging and
their overexpression induces cellular senescence (Grillari et al.,
2010).
In addition, we found some miRNAs involved with an inflam-
matory response such as miR-146a and miR-146b that display
altered levels in plasma of both groups of oldmice. This is particu-
larly relevant considering that it has been established that inflam-
mation is a condition closely related to the aging process. miR-
146a and 146b are NF-κB sensitive-miRNAs that suppress the
immune response by inhibiting the pro-inflamatory immune cell
signaling (Taganov et al., 2006). Interestingly, miR-146a displays
a higher abundance in the 14–15-month old WT and a lower
abundance in the 14–15-month 3xTg-AD as compared to their
respective group of young mice. These bidirectional modulation
agrees with recent data indicating that miR-146a is elevated in
senescence models (Olivieri et al., 2013; Rippo et al., 2014), while
it is decreased in AD (Kiko et al., 2014; Müller et al., 2014). A
similar case is miR-34a, which is present with lower abundance in
the 14–15-month 3xTg-AD mice as compared to the 2–3-month
3xTg-AD while showing a trend to increase with age in the WT.
Higher levels of this miRNA are found in the brain, blood cells
and plasma of old mice (Li et al., 2011) but the loss of miR-
34a induces neurodegenerative phenotypes in Drosophila, and its
overexpression induces longevity (Liu et al., 2012). Remarkably,
lower levels of miR-34a have been reported in AD cases (Kiko
et al., 2014; Müller et al., 2014).
Thus, it is evident that the age-dependent evolution of AD-like
pathology produces specific changes in the circulating miRNA
profile of the 3xTg-AD mice. As a consequence, we identified dif-
ferences in the abundance of 10 miRNAs when comparing plasma
samples of the 14–15- month 3xTg-AD with the 14–15-month
WT mice. Most of the alterations observed in the aged 3xTg-AD
mice consist on the reduction of plasmatic miRNAs levels as com-
pared to the aged WT. This is in agreement with previous reports
from brain, CSF and serum/plasma samples of AD patients where
miR-15, miR-29, miR-101, miR-106, miR-107, and miR-181 have
been shown to be diminished (Cogswell et al., 2008; Hébert et al.,
2008; Wang et al., 2008b, 2011; Geekiyanage and Chan, 2011;
Geekiyanage et al., 2011; Kumar et al., 2013; Tan et al., 2013;
Burgos et al., 2014; Kiko et al., 2014).
Table 1 | AD-like pathology-related miRNAs identified in this study and previously associated with AD.
This study Previous studies
miRNA Sample Lower/ Sample Lower/ References Target
Higher Higher
miR-132 Plasma of 3xTg-AD and WT mice
of 2–3 and 14–15 months
− AD brain − Cogswell et al., 2008 p250-GAP
AD neocortex − Hébert et al., 2013
AD CSF − Burgos et al., 2014
miR-138 − AD CSF − Burgos et al., 2014 APT1
miR-139 − AD CSF − Burgos et al., 2014
miR-146a − AD CSF/plasma − Kiko et al., 2014 IRAK-1TRAF6
AD CFS − Müller et al., 2014
AD hippocampus ±
miR-146b − AD CSF − Cogswell et al., 2008
AD brain −
miR-29a − AD cortex − Hébert et al., 2008 BACE1
AD serum − Geekiyanage et al., 2011
AD CSF + Kiko et al., 2014
miR-29c − AD cortex − Hébert et al., 2008
The table contains data obtained from this study (left) and collected from others (right). It indicates the miRNA, the sample used for determination, the abundance
respect to the control cases and the reference of the other studies. It also contains the mRNA-target for the miRNA: p250-GAP, a brain-enriched GTPase-activating
protein for Rho Family GTPases involved in the N-Methyl-d-aspartate receptor (NMDAR) signaling; APT1, acyl protein thioesterase 1, an enzyme regulating the
palmitoylation status of proteins that are known to function at the synapse; IRAK1, interleukin-1 receptor-associated kinase 1, a kinase that associates with the
interleukin-1 receptor upon stimulation which is responsible for interleukin-1 transcription of NFkB; TRAF6, TNF receptor associated factor 6 involved in the regulation
of inflammation response and apoptosis; BACE1, β-secretase, a protease that cleaves the APP in the β site to produce the Aβ peptide in the amyloidogenic APP
processing.
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Some of the 10 AD-like pathology-related miRNAs identi-
fied in this study have been previously associated with AD in
different studies (Table 1). For instance, the miR-29 cluster is
decreased in brain samples of AD patients, which correlates with
an increase of the levels of the β-sercretase protein. Furthermore,
members of this cluster have been shown to regulate the levels of
the β-secretase in vitro (Hébert et al., 2008). Levels of miR-146a
and miR-146b have been reported diminished in brain, CFS and
plasma of AD patients (Cogswell et al., 2008; Kiko et al., 2014;
Müller et al., 2014). These miRNAs are related to the inflam-
matory response, and may constitute an interesting result since
neuroinflammation is a prevalent and early pathological feature
of AD (Lukiw et al., 2008). In agreement with our results, lower
levels of miR-132, miR-138 y miR-139 have been reported in
AD brain and CFS samples (Cogswell et al., 2008; Burgos et al.,
2014). miR-132 has been reported to have an anti-inflammatory
effect, blocking acetylcholinesterase, elevating acetylcholine levels
and consequently blocking NF-kB (Shaked et al., 2009). In neu-
rons, miR-132 and miR-138 are expressed in response to synaptic
activity and have a role in the modulation of morphologic events
of neuroplasticity taking place in memory and cognition pro-
cesses (Wayman et al., 2008; Siegel et al., 2009; Edbauer et al.,
2010; Impey et al., 2010; Hansen et al., 2012; Bicker et al., 2014).
Synapses represent vulnerable structures in AD and several patho-
logic molecular events take place in these sites comprising their
function (Selkoe, 2002). Since memory and cognition are highly
impaired in AD, the lower abundance of miR-132 and miR-138
result very interesting for analyzing the evolution of AD at a
molecular level. It would be therefore interesting to determine
changes in plasmatic miRNAs with the status of patients already
showing mild cognitive impairment in order to advance the early
diagnosis of AD.
In this work we used a pre-designed miRNA microarray plat-
form, which included a restricted number of miRNAs previously
associated to different neuropathologies. Other miRNAs not
included in this design may be associated also to AD. However,
and since to our knowledge this is the first study of circulating
miRNAs in this transgenicmodel, we decided to incorporatemiR-
NAs that have been already associated to several neuropatholo-
gies. It is clear that given the multifactorial nature of the disease,
it is likely that not only a single biomarker will meet the needs
for clinical diagnosis. Here we propose that a relative simple,
non-invasive procedure may provide useful information about
the AD pathophysiology, detection, and evolution. Thus, combin-
ing a panel of miRNA detection with additional biomarkers may
increase the sensitivity and specificity for early AD diagnosis.
CONCLUSION
The aim of this study was to identify changes in the circulating
miRNA profile of a transgenic mouse model of AD in two differ-
ent stages of the evolution of AD-like pathology. Using these two
time-windows it was not possible to detect early modifications in
miRNA levels associated with prodromal AD. However, we distin-
guish variations in different miRNAs once the AD-like pathology
is established which advances the molecular biomarkers field.
Most of the miRNAs we found as potentially interesting biomark-
ers for AD have no identified targets that may be assoiciated to the
disease and their role in the pathological mechanisms taking place
in AD remains unknown. Our results however shed light on sub-
tle molecular modifications associated to pathological aging and
open new venues for studying the role of particular circulating
miRNAs in the evolution of AD.
ACKNOWLEDGMENTS
We thank Perla Moreno-Castilla, Patricia Ferrera, and Gonzalo
Acero for technical assistance. This work was supported by
grants from CONACyT-176589 and PAPIIT-IA200312 to AZ,
CONACyT-127822 to LV, CONACyT-155242 and DGAPA-
IN209413 to FB-R. SG-M received anMSc degree fellowship from
CONACyT. Additional support was provided by the Program
“Posgrado en Ciencias Bioquímicas” at the Universidad Nacional
Autónoma de México (UNAM).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: http://www.frontiersin.org/journal/10.3389/fncel.2015.
00053/abstract
REFERENCES
Alexandrov, P. N., Dua, P., Hill, J. M., Bhattacharjee, S., Zhao, Y., and Lukiw, W.
J. (2012). microRNA (miRNA) speciation in Alzheimer’s disease (AD) cere-
brospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol.
3, 365–373.
Alkalay, A., Rabinovici, G. D., Zimmerman, G., Agarwal, N., Kaufer, D.,
Miller, B. L., et al. (2013). Plasma acetylcholinesterase activity correlates
with intracerebral β-amyloid load. Curr. Alzheimer Res. 10, 48–56. doi:
10.2174/1567205011310010007
Ameres, S. L., and Zamore, P. D. (2013). Diversifying microRNA sequence and
function. Nat. Rev. Mol. Cell Biol. 14, 475–488. doi: 10.1038/nrm3611
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F.,
et al. (2011). Argonaute2 complexes carry a population of circulating microR-
NAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U.S.A. 108,
5003–5008. doi: 10.1073/pnas.1019055108
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., and Jones,
E. (2011). Alzheimer’s disease. Lancet. 377, 1019–1031. doi: 10.1016/S0140-
6736(10)61349-9
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell
136, 215–233. doi: 10.1016/j.cell.2009.01.002
Beveridge, N. J., Gardiner, E., Carroll, A. P., Tooney, P. A., and Cairns, M. J. (2010).
Schizophrenia is associated with an increase in cortical microRNA biogenesis.
Mol. Psychiatry 15, 1176–1189. doi: 10.1038/mp.2009.84
Bicker, S., Lackinger, M., Weiss, K., and Schratt, G. (2014). MicroRNA-132, -134,
and -138: a microRNA troika rules in neuronal dendrites. Cell. Mol. Life Sci. 71,
3987–4005. doi: 10.1007/s00018-014-1671-7
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., et al.
(2014). Profiles of extracellular miRNA in cerebrospinal fluid and serum
from patients with Alzheimer’s and Parkinson’s diseases correlate with dis-
ease status and features of pathology. PLoS ONE 9:e94839. doi: 10.1371/jour-
nal.pone.0094839
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. (2008). Characterization
of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18, 997–1006. doi: 10.1038/cr.2008.282
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008).
Identification of miRNA changes in Alzheimer’s disease brain and CSF yields
putative biomarkers and insights into disease pathways. J. Alzheimers. Dis. 14,
27–41.
Dekosky, S. T., Scheff, S. W., and Styren, S. D. (1996). Structural correlates
of cognition in dementia: quantification and assessment of synapse change.
Neurodegeneration 5, 417–421. doi: 10.1006/neur.1996.0056
Edbauer, D., Neilson, J. R., Foster, K. A., Wang, C. F., Seeburg, D. P., Batterton,
M. N., et al. (2010). Regulation of synaptic structure and function by
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 53 | 7
Garza-Manero et al. Time-dependent miRNA alterations in an Alzheimer’s disease model
FMRP-associatedmicroRNAsmiR-125b andmiR-132.Neuron 65, 373–384. doi:
10.1016/j.neuron.2010.01.005
Fabian, M. R., and Sonenberg, N. (2012). The mechanics of miRNA-mediated gene
silencing: a look under the hood of miRISC. Nat. Struct. Mol. Biol. 19, 586–593.
doi: 10.1038/nsmb.2296
Geekiyanage, H., and Chan, C. (2011). MicroRNA-137/181c regulates serine palmi-
toyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer’s
disease. J. Neurosci. 31, 14820–14830. doi: 10.1523/JNEUROSCI.3883-
11.2011
Geekiyanage, H., Jicha, G. A., Nelson, P. T., and Chan, C. (2011). Blood serum
miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp. Neurol. 235,
491–496. doi: 10.1016/j.expneurol.2011.11.026
Giraldez, A. J., Cinalli, R. M., Glasner, M. E., Enright, A. J., Thomson, J. M.,
Baskerville, S., et al. (2005). MicroRNAs regulate brain morphogenesis in
zebrafish. Science 308, 833–838. doi: 10.1126/science.1109020
Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani,
L., et al. (1991). Segregation of a missense mutation in the amyloid precur-
sor protein gene with familial Alzheimer’s disease. Nature 349, 704–706. doi:
10.1038/349704a0
Grillari, J., Hackl, M., and Grillari-Voglauer, R. (2010). miR-17-92 cluster: ups and
downs in cancer and aging. Biogerontology 11, 501–506. doi: 10.1007/s10522-
010-9272-9
Hansen, K. F., Karelina, K., Sakamoto, K., Wayman, G. A., Impey, S., and Obrietan,
K. (2012). miRNA-132: a dynamic regulator of cognitive capacity. Brain Struct.
Funct. 218, 817–831. doi: 10.1007/s00429-012-0431-4
Hébert, S. S., Horre, K., Nicolai, L., Papadopoulou, A. S., Mandemakers, W.,
Silahtaroglu, A. N., et al. (2008). Loss of microRNA cluster miR-29a/b-
1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-
secretase expression. Proc. Natl. Acad. Sci. U.S.A. 105, 6415–6420. doi:
10.1073/pnas.0710263105
Hébert, S. S., Wang, W-X., Zhu, Q., and Nelson, P. T. (2013). A study of
small RNAs from cerebral neocortex of pathology-verified Alzheimer’s dis-
ease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar
dementia, and non-demented human controls. J. Alzheimer’s Dis. 35, 335–348.
doi: 10.3233/JAD-122350
Impey, S., Davare, M., Lesiak, A., Fortin, D., Ando, H., Varlamova, O., et al.
(2010). An activity-induced microRNA controls dendritic spine formation
by regulating Rac1-PAK signaling. Mol. Cell. Neurosci. 43, 146–156. doi:
10.1016/j.mcn.2009.10.005
Johnson, R., Zuccato, C., Belyaev, N. D., Guest, D. J., Cattaneo, E., and Buckley,
N. J. (2008). A microRNA-based gene dysregulation pathway in Huntington’s
disease. Neurobiol. Dis. 29, 438–445. doi: 10.1016/j.nbd.2007.11.001
Kato, M., Chen, X., Inukai, S., Zhao, H., and Slack, F. J. (2011). Age-associated
changes in expression of small, noncoding RNAs, including microRNAs, in
C. elegans. RNA 17, 1804–1820. doi: 10.1261/rna.2714411
Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., and Miyazawa, T.
(2014). MicroRNAs in plasma and cerebrospinal fluid as potential markers for
Alzheimer’s disease. J. Alzheimers. Dis. 39, 253–259. doi: 10.3233/JAD-130932
Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E., et al. (2007).
A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317,
1220–1224. doi: 10.1126/science.1140481
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P.,
et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh
Compound-B. Ann. Neurol. 55, 306–319. doi: 10.1002/ana.20009
Kumar, P., Dezso, Z., Mackenzie, C., Oestreicher, J., Agoulnik, S., Byrne, M., et al.
(2013). Circulating miRNA biomarkers for Alzheimer’s disease. PLoS ONE
8:e69807. doi: 10.1371/journal.pone.0069807
Lawrie, C. H., Gal, S., Dunlop, H.M., Pushkaran, B., Liggins, A. P., Pulford, K., et al.
(2008). Detection of elevated levels of tumour-associated microRNAs in serum
of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141, 672–675.
doi: 10.1111/j.1365-2141.2008.07077.x
Leidinger, P., Backes, C., Deutscher, S., Schmitt, K., Mueller, S. C., Frese, K., et al.
(2013). A blood based 12-miRNA signature of Alzheimer disease patients.
Genome Biol. 14:R78. doi: 10.1186/gb-2013-14-7-r78
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W.
H., et al. (1995). Candidate gene for the chromosome 1 familial Alzheimer’s
disease locus. Science 269, 973–977. doi: 10.1126/science.7638622
Li, X., Khanna, A., Li, N., and Wang, E. (2011). Circulatory miR34a as an
RNAbased, noninvasive biomarker for brain aging. Aging 3, 985–1002.
Liu, N., Landreh, M., Cao, K., Abe, M., Hendriks, G. J., Kennerdell, J. R., et al.
(2012). The microRNA miR-34 modulates ageing and neurodegeneration in
Drosophila. Nature 482, 519–523. doi: 10.1038/nature10810
Lukiw, W. J. (2007). Micro-RNA speciation in fetal, adult and Alzheimer’s dis-
ease hippocampus. Neuroreport 18, 297–300. doi: 10.1097/WNR.0b013e3280
148e8b
Lukiw, W. J., Zhao, Y., and Cui, J. G. (2008). An NF-kappaB-sensitive
micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and
in stressed human brain cells. J. Biol. Chem. 283, 31315–31322. doi:
10.1074/jbc.M805371200
Martinez, I., Cazalla, D., Almstead, L. L., Steitz, J. A., and Dimaio, D.
(2011). miR-29 and miR-30 regulate B-Myb expression during cellular senes-
cence. Proc. Natl. Acad. Sci. U.S.A. 108, 522–527. doi: 10.1073/pnas.10173
46108
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-
Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based
markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105, 10513–10518.
doi: 10.1073/pnas.0804549105
Müller, M., Kuiperij, H. B., Claassen, J. A., Kusters, B., and Verbeek, M. M.
(2014). MicroRNAs in Alzheimer’s disease: differential expression in hip-
pocampus and cell-free cerebrospinal fluid. Neurobiol. Aging 35, 152–158. doi:
10.1016/j.neurobiolaging.2013.07.005
Nunez-Iglesias, J., Liu, C. C., Morgan, T. E., Finch, C. E., and Zhou, X. J. (2010).
Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer’s
disease cortex reveals altered miRNA regulation. PLoS ONE 5:e8898. doi:
10.1371/journal.pone.0008898
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R.,
et al. (2003). Triple-transgenic model of Alzheimer’s disease with plaques and
tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409–421. doi:
10.1016/S0896-6273(03)00434-3
Olivieri, F., Lazzarini, R., Recchioni, R., Marcheselli, F., Rippo, M. R., Di Nuzzo, S.,
et al. (2013). MiR-146a as marker of senescence-associated pro-inflammatory
status in cells involved in vascular remodelling. Age 35, 1157–1172. doi:
10.1007/s11357-012-9440-8
Rippo, M. R., Olivieri, F., Monsurro, V., Prattichizzo, F., Albertini, M. C., and
Procopio, A. D. (2014). MitomiRs in human inflamm-aging: a hypothesis
involving miR-181a, miR-34a and miR-146a. Exp. Gerontol. 56, 154–163. doi:
10.1016/j.exger.2014.03.002
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y.,
et al. (1995). Familial Alzheimer’s disease in kindreds with missense mutations
in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene.
Nature 376, 775–778. doi: 10.1038/376775a0
Schultz, J., Lorenz, P., Gross, G., Ibrahim, S., and Kunz, M. (2008). MicroRNA
let-7b targets important cell cycle molecules in malignant melanoma cells
and interferes with anchorage-independent growth. Cell Res. 18, 549–557. doi:
10.1038/cr.2008.45
Selkoe, D. J. (2001). Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev.
81, 741–766.
Selkoe, D. J. (2002). Alzheimer’s disease is a synaptic failure. Science 298, 789–791.
doi: 10.1126/science.1074069
Shaked, I., Meerson, A., Wolf, Y., Avni, R., Greenberg, D., Gilboa-Geffen,
A., et al. (2009). MicroRNA-132 potentiates cholinergic anti-inflammatory
signaling by targeting acetylcholinesterase. Immunity 31, 965–973. doi:
10.1016/j.immuni.2009.09.019
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda,
M., et al. (1995). Cloning of a gene bearing missense mutations in early-
onset familial Alzheimer’s disease. Nature 375, 754–760. doi: 10.1038/
375754a0
Siegel, G., Obernosterer, G., Fiore, R., Oehmen, M., Bicker, S., Christensen, M.,
et al. (2009). A functional screen implicates microRNA-138-dependent regula-
tion of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis.
Nat. Cell Biol. 11, 705–716. doi: 10.1038/ncb1876
Taganov, K. D., Boldin, M. P., Chang, K. J., and Baltimore, D. (2006). NF-
kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to
signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 103,
12481–12486. doi: 10.1073/pnas.0605298103
Tan, L., Yu, J. T., Liu, Q. Y., Tan, M. S., Zhang, W., Hu, N., et al. (2013). Circulating
miR-125b as a biomarker of Alzheimer’s disease. J. Neurol. Sci. 336, 52–56. doi:
10.1016/j.jns.2013.10.002
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 53 | 8
Garza-Manero et al. Time-dependent miRNA alterations in an Alzheimer’s disease model
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., Deteresa, R., Hill, R., et al.
(1991). Physical basis of cognitive alterations in Alzheimer’s disease: synapse
loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–580.
doi: 10.1002/ana.410300410
Thomson, J. M., Parker, J., Perou, C. M., and Hammond, S. M. (2004). A custom
microarray platform for analysis of microRNA gene expression.Nat. Methods 1,
47–53. doi: 10.1038/nmeth704
Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., and Lotvall, J.
O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659. doi:
10.1038/ncb1596
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., and Remaley,
A. T. (2011). MicroRNAs are transported in plasma and delivered to recipi-
ent cells by high-density lipoproteins. Nat. Cell Biol. 13, 423–433. doi: 10.1038/
ncb2210
Wang, G., Van Der Walt, J. M., Mayhew, G., Li, Y. J., Zuchner, S., Scott, W. K.,
et al. (2008a). Variation in the miRNA-433 binding site of FGF20 confers risk
for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet.
82, 283–289. doi: 10.1016/j.ajhg.2007.09.021
Wang, W. X., Huang, Q., Hu, Y., Stromberg, A. J., and Nelson, P. T. (2011). Patterns
of microRNA expression in normal and early Alzheimer’s disease human tem-
poral cortex: white matter versus gray matter. Acta Neuropathol. 121, 193–205.
doi: 10.1007/s00401-010-0756-0
Wang, W. X., Rajeev, B. W., Stromberg, A. J., Ren, N., Tang, G., Huang, Q., et al.
(2008b). The expression of microRNA miR-107 decreases early in Alzheimer’s
disease and may accelerate disease progression through regulation of beta-site
amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 28, 1213–1223. doi:
10.1523/JNEUROSCI.5065-07.2008
Wayman, G. A., Davare, M., Ando, H., Fortin, D., Varlamova, O., Cheng, H. Y.,
et al. (2008). An activity-regulated microRNA controls dendritic plasticity by
down-regulating p250GAP. Proc. Natl. Acad. Sci. U.S.A. 105, 9093–9098. doi:
10.1073/pnas.0803072105
Yoo, A. S., Staahl, B. T., Chen, L., and Crabtree, G. R. (2009). MicroRNA-mediated
switching of chromatin-remodelling complexes in neural development. Nature
460, 642–646. doi: 10.1038/nature08139
Zhao, C., Sun, G., Li, S., and Shi, Y. (2009). A feedback regulatory loop involving
microRNA-9 and nuclear receptor TLX in neural stem cell fate determination.
Nat. Struct. Mol. Biol. 16, 365–371. doi: 10.1038/nsmb.1576
Conflict of Interest Statement: The Guest Associate Editor Rosalinda Guevara-
Guzmán declares that, despite being affiliated to the same institution as authors
Sylvia Garza-Manero, Clorinda Arias, Federico Bermúdez-Rattoni, Luis Vaca and
Angélica Zepeda, the review process was handled objectively and no conflict of
interest exists. The authors declare that the research was conducted in the absence
of any commercial or financial relationships that could be construed as a potential
conflict of interest.
Received: 17 October 2014; accepted: 03 February 2015; published online: 19 February
2015.
Citation: Garza-Manero S, Arias C, Bermúdez-Rattoni F, Vaca L and Zepeda A
(2015) Identification of age- and disease-related alterations in circulating miRNAs in
a mouse model of Alzheimer’s disease. Front. Cell. Neurosci. 9:53. doi: 10.3389/fncel.
2015.00053
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2015 Garza-Manero, Arias, Bermúdez-Rattoni, Vaca and Zepeda.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 53 | 9
